Clinical trials: TACE
Carcinoma, Hepatocellular
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course…
- Trial name
- SUCCESS (NCT01839630)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of Sorafenib combined with transarterial chemoembolization as adjuvant treatment for resectable advanced…
- Trial name
- SOURCE (NCT04143191)
- Testing
- Sorafenib, Transarterial chemoembolization
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with radiofrequency ablation (RFA) and transcatheter arterial chemoembolization(TACE) in patients with…
- Trial name
- NCT04157140
- Testing
- Anlotinib, TACE+RFA
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Jinglong Chen
HCC, Transarterial Chemoembolization
A New Conception About Individualized Treatment Allocation for HCC
The current guidelines on hepatocellular carcinoma (HCC) aimed to build effective prognostic stratification strategies to guide therapeutic allocation; however, the current guidelines did not consider the simultaneous comparison…
- Conditions
- HCC, Transarterial Chemoembolization, Resection
- Trial name
- PTA4HCC (NCT06008548)
- Testing
- TACE
- Volunteers
- 4,991 people
- Sponsor
- Tang-Du Hospital
Hepatocellular Carcinoma, HCC
Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant
This study will compare stereotactic body radiation therapy (SBRT) to trans-arterial chemoembolization (TACE) as a bridging strategy for patients with HCC undergoing orthotopic liver transplantation.
- Trial name
- SBRTvsTACE (NCT02182687)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Lahey Clinic
Colon Cancer Liver Metastasis
Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer
This is a multicentre, open labeled, single arm study to determine effectiveness and safety of chemoembolization with Irinotecan-Eluting Bead(DEBIRI) in the treatment of unresectable liver metastases in patients with colorectal…
- Trial name
- DEBIRI-CRLM (NCT03175016)
- Testing
- TACE, Irinotecan, eluting-bead
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
M-TACE Treatment for Unresectable Hepatocellular Carcinoma
This study aims to investigate the safety and efficacy of transarterial chenmoembolization（TACE） combined with microspheres for unresectable hepatocellular carcinoma(HCC).
- Trial name
- NCT05875558
- Testing
- M-TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with TACE as adjuvant therapy of patients with hepatocellular carcinoma at a high risk of recurrence after radical…
- Trial name
- NCT05161143
- Testing
- Donafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma
Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion
The purpose of this study is to compare the effects of different multimodality therapy strategies (initial hepatectomy followed by transcatheter hepatic arterial chemoembolization and/or local regional treatments compare with…
- Trial name
- MDTforHCC (NCT00501813)
- Testing
- Hepatectomy, TACE combined with local regional therapies without hepatectomy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection
- Trial name
- NCT02588755
- Testing
- TACE+Tegafur, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma (HCC)
Multiparametric MRI for Characterization of Hepatocellular Carcinoma
This prospective observational study investigates using multiparametric magnetic resonance imaging (MRI) to improve the characterization and management of therapy for hepatocellular carcinoma (HCC).
- Trial name
- NCT06999174
- Testing
- Multiparametric MRI
- Where
- Germany
- Volunteers
- 128 people
- Sponsor
- University Hospital Muenster
Antibiotic Prophylaxis
Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma
This study aims to determine the effectiveness of prophylactic antibiotic use for TACE and occurrence of postoperative liver abscess. There would be two comparison groups.
- Trial name
- NCT05654896
- Testing
- Ceftriaxone Sodium
- Where
- Pakistan
- Volunteers
- 158 people
- Sponsor
- Nadeem Iqbal
Vascular Access Device Complications
Radial Access for Abdominopelvic Vascular Intervention
To evaluate the safety and efficacy of R.A.V.I.(radial access for abdominopelvic vascular intervention), and evaluate the feasibility and safety of repeated radial artery intervention
- Trial name
- NCT05956860
- Testing
- abdominopelvic vascular intervention through the radial artery access
- Where
- China
- Volunteers
- 1,143 people
- Sponsor
- Zhongda Hospital
Unresectable Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
This is a retrospective, multicenter, real-world cohort study designed to evaluate the effectiveness and safety of atezolizumab plus bevacizumab (Atezo+Bev) combined with various locoregional therapies (LRTs), including…
- Trial name
- ISMIO001 (NCT07204327)
- Testing
- Atezo+Bev plus Locoregional Therapy
- Where
- China
- Volunteers
- 1,136 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Follow up After TACE by Elastography and Color Doppler.
To determine accuracy of elastography and color Doppler in follow up of patients with HCC after TACE comparing with modified RECIST criteria.
- Trial name
- NCT06070623
- Testing
- US
- Volunteers
- 54 people
- Sponsor
- Assiut University
Precision Cells, Chemotherapy
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Objectives: To evaluate the safety and effectiveness of cell therapy using precision cells to treat Advanced Lung Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age…
- Conditions
- Precision Cells, Chemotherapy, Advanced Lung Cancer
- Trial name
- NCT02862587
- Testing
- Chemotherapy, precision cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai International Medical Center
Advanced Hepatocellular Carcinoma
TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.
This study will evaluate the safety and effect of transcatheter arterial chemoembolization (TACE)combined with percutaneous transhepatic PD-1 knockout engineered T cell infusion in the Paitents with advanced hepatocellular…
- Trial name
- NCT04417764
- Testing
- Transcatheter arterial chemoembolization, PD-1 knockout engineered T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Central South University
Hepatocellular Carcinoma
A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)
This is a real world study to determine the short-term efficacy and safety of Elaboration transcatheter arterial chemoembolization (E-TACE) for hepatocellular carcinoma (HCC)
- Trial name
- NCT06023147
- Testing
- E-TACE
- Where
- 27 sites in China
- Volunteers
- 298 people
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma
Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH
The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on the prognosis of patients with microvascular invasion presence(MVI) and overexpression of Aspartate-β-hydroxylase(ASPH).
- Trial name
- NCT02587884
- Testing
- TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Face Cancer
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) has been the standard treatment modality for HCC aiming at clinical cure.
- Trial name
- NCT01833299
- Testing
- TACE-Sorafenib group, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University